GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » Credit Losses Provision

NeuroSense Therapeutics (NeuroSense Therapeutics) Credit Losses Provision


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Credit Losses Provision?

Credit Losses Provision only applies to banks.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.